These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37275454)

  • 21. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first- and second-line treatment of advanced colorectal cancer.
    Jonker D; Rumble RB; Maroun J;
    Curr Oncol; 2006 Oct; 13(5):173-84. PubMed ID: 22792014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial.
    Li J; Qin S; Xu RH; Shen L; Xu J; Bai Y; Yang L; Deng Y; Chen ZD; Zhong H; Pan H; Guo W; Shu Y; Yuan Y; Zhou J; Xu N; Liu T; Ma D; Wu C; Cheng Y; Chen D; Li W; Sun S; Yu Z; Cao P; Chen H; Wang J; Wang S; Wang H; Fan S; Hua Y; Su W
    JAMA; 2018 Jun; 319(24):2486-2496. PubMed ID: 29946728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Tegafur, Gimeracil and Oteracil Potassium Capsules combined with Calf Spleen Extractive Injection on serum VEGF and MMP-9 in patients with advanced gastric cancer.
    Zhang Y; Zhong Q; Luo X; Zhang W
    Am J Transl Res; 2022; 14(11):7969-7976. PubMed ID: 36505301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A clinical exploration of neoadjuvant chemotherapy with tegafur, gimeracil, and oteracil potassium capsules combined with oxaliplatin for advanced gastric cancer.
    Lv X; Zhang L; Huang R; Song W
    Int J Clin Exp Med; 2015; 8(10):19030-6. PubMed ID: 26770529
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of advanced intrahepatic cholangiocarcinoma with sintilimab combined with tegafur-gimeracil-oteracil potassium capsules (S-1): a case report.
    Liu J; Wang C; Cao L; Li S
    Ann Palliat Med; 2020 Mar; 9(2):497-503. PubMed ID: 32233637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A single-center retrospective analysis of the efficacy and safety of a modified regimen of irinotecan plus S-1 (IRIS) with molecular targeting agents as second-line chemotherapy in Japanese patients with recurrent or nonresectable colorectal cancer.
    Higami S; Mukai M; Yokoyama D; Uda S; Abe R; Mamuro N; Kishima K; Hasegawa S; Tajima T; Nomura E; Makuuchi H
    J Gastrointest Oncol; 2023 Apr; 14(2):663-675. PubMed ID: 37201062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies.
    Kobayakawa M; Kojima Y
    Onco Targets Ther; 2011; 4():193-201. PubMed ID: 22162925
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of alternate-day treatment with TS-1
    Nishiyama Y; Fukuyama Y; Maruo T; Yoda S; Iwano M; Kawarai S; Kayanuma H; Orito K
    J Vet Med Sci; 2021 Aug; 83(8):1206-1211. PubMed ID: 34148911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial.
    Winther SB; Liposits G; Skuladottir H; Hofsli E; Shah CH; Poulsen LØ; Ryg J; Osterlund P; Berglund Å; Qvortrup C; Glimelius B; Sorbye H; Pfeiffer P
    Lancet Gastroenterol Hepatol; 2019 May; 4(5):376-388. PubMed ID: 30852136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Assessment of quality of life by questionnaires between S-1/CPT-11 and mFOLFOX6 in patients with advanced colorectal cancer].
    Tokunaga Y; Sasaki H; Matsueda S
    Gan To Kagaku Ryoho; 2011 Jul; 38(7):1127-31. PubMed ID: 21772096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
    Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
    Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer.
    Wulaningsih W; Wardhana A; Watkins J; Yoshuantari N; Repana D; Van Hemelrijck M
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD008593. PubMed ID: 26869023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toripalimab and fruquintinib therapy for colorectal cancer after failed multiline chemotherapies: a case report.
    Kong LZ; Zheng Y; Li K
    Immunotherapy; 2024 Feb; 16(2):107-114. PubMed ID: 38112011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of S-1-based sequential combination chemotherapy including oxaliplatin plus bevacizumab and irinotecan with or without cetuximab for metastatic colorectal cancer: the SOBIC trial.
    Nakamoto Y; Noda M; Mikami R; Tokunaga Y; Okumoto T; Kawamura T; Fujiwara H; Doi S; Tomita N
    Int J Clin Oncol; 2020 Jul; 25(7):1285-1290. PubMed ID: 32200481
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in the FRESCO trial.
    Qin S; Li J; Bai Y; Deng Y; Yang L; Xu RH; Zhong H; Chen Z; Pan H; Guo W; Shu Y; Xu J; Peng C; Chen Y; Li H; Wang N; Guo X; Peng M; Fan S; Shen L
    Future Oncol; 2021 May; 17(15):1923-1931. PubMed ID: 33563040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study.
    Ma S; Chen R; Duan L; Li C; Yang T; Wang J; Zhao D
    J Gastrointest Oncol; 2023 Apr; 14(2):1052-1063. PubMed ID: 37201046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study.
    Deng YY; Zhang XY; Zhu PF; Lu HR; Liu Q; Pan SY; Chen ZL; Yang L
    Front Oncol; 2023; 13():1097911. PubMed ID: 36937443
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness and safety of tegafur-gimeracil-oteracil potassium (TS-1) for metastatic breast cancer: a single-center retrospective study.
    Ishizuna K; Ninomiya J; Ogawa T; Kojima M; Tsuji E; Kawashima M; Nozaki M; Yamagishi H; Ueda Y
    Gan To Kagaku Ryoho; 2014 Dec; 41(13):2577-82. PubMed ID: 25596051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
    Takumoto Y; Sasahara Y; Narimatsu H; Akazawa M
    JAMA Netw Open; 2022 Jan; 5(1):e2145515. PubMed ID: 35099549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.